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Short summary  
A mass drug administration campaign against malaria (combined with indoor residual spraying) was 
carried out in 2018 in Grande-Anse, Haiti. The campaign was significantly associated with an 






















Haiti is planning targeted interventions to accelerate progress towards malaria elimination. In the 
most affected Department (Grande-Anse), a combined mass drug administration (MDA) and indoor 
residual spraying (IRS) campaign was launched in October 2018. This study assessed the intervention 
effectiveness in reducing P. falciparum prevalence.  
Methods. 
An ecological quasi-experimental study was designed, using a pre- and post-test with 
nonrandomized control group. Surveys were conducted in November 2017 in a panel of easy access 
groups (25 schools and 16 clinics), and were repeated 2-6 weeks after the campaign, in November 
2018. Single-dose sulfadoxine-pyrimethamine and primaquine was used for MDA, and primiphos 
methyl as insecticide for IRS.  
Results. 
A total of 10,006 participants were recruited. 52% of the population in the intervention area 
reported having received MDA. Prevalence diminished between 2017 and 2018 in both areas, but 
the reduction was significantly larger in the intervention area (ratio of adjusted risk ratios = 0.32, 
95% confidence interval [0.104 - 0.998]).  
Conclusions. 
Despite a moderate coverage, the campaign was effective in reducing P. falciparum prevalence 
immediately after one round. Targeted MDA+IRS are useful in pre-elimination settings to rapidly 


























Haiti is one of the only two Caribbean countries with endemic malaria transmission. Most (>99%) of 
infections are due to P. falciparum, with only sporadic reports of P. vivax and P. malariae1,2) and 
Anopheles albimanus the main vector3-5. The country is committed to eliminating malaria, thanks to 
a favorable context including parasite prevalence detected by polymerase chain reaction (PCR) 
consistently estimated at <1% in national surveys1,6-11. 
To that end, the National Malaria Control Programme (NMCP) in Haiti has implemented a number of 
interventions over the last decade. System-wide changes were introduced, such as the introduction 
of rapid diagnostic tests (RDT), the addition of primaquine (PQ – a 0.75 mg/kg in a single dose) to 
chloroquine (25 mg/kg administered over three days) as first-line treatment, the strengthening of 
surveillance and laboratory capacities, and a nationwide distribution of long-lasting insecticidal nets 
(LLINs) in 2012, with a top-up distribution in high-transmission areas in mid-201712-14. 
Targeted interventions have also been introduced since malaria transmission is highly 
heterogeneous in the country15-17. In 2015, the Malaria Zero Consortium 
(https://www.malariazeroalliance.org/) was created to support the acceleration towards elimination 
and provide formative evidence that will assist tailoring strategies12,18-20. Mass treatment campaigns 
were considered, since studies conducted in low-endemic settings have shown their feasibility, 
effectiveness in reducing malaria prevalence, and potential contribution to shorten the timeline to 
elimination if combined with other interventions21-24. MDA is well suited to elimination settings 
because of the asymptomatic reservoir; the high proportion of low density infections makes 
detection and targeting challenging25. However, models indicate that the positive effects of MDA in 
low transmission settings are temporary26. Therefore, the World Health Organization recommends 
MDA in areas approaching interruption of transmission, with limited risk of re-importation, and after 
scale-up of other interventions27,28.  
As recommended, targeted MDA (tMDA) was only considered in Haiti once the passive surveillance 
system was strengthened, and after the introduction of community case management and user fee 
removal in health facilities28. Aiming to rapidly reduce malaria transmission in the most afflicted 
Department, a tMDA campaign using sulfadoxine-pyrimethamine (SP) and single low-dose 
primaquine (SLD-PQ) was implemented in a single round. It was implemented on top of a vector 
control strategy that included prior population-wide distribution of LLINS and targeted indoor 
residual spraying (tIRS) using the insecticide primiphos methyl29. The campaign targeted the entire 
population residing in the areas of highest malaria transmission. There is some evidence that MDA 
campaigns are acceptable and feasible in Haiti12,30. However, this is the first time in decades that a 
malaria MDA has actually been used in Haiti. We used an ecological quasi-experimental study design 
(pre-post with non-randomized control group) to evaluate the immediate effects of this targeted 























The intervention campaign took place October 10 - November 6, 2018, in five communes of Grande-
Anse Department, just before the annual seasonal peak of malaria. This department has the highest 
malaria incidence rate in the country (18.1 per 1,000 in 2017, compared to 1.7 per 1,000 nationally). 
The pilot area comprised five communes selected based on epidemiological, spatial, logistical and 
social factors (Figure 1). Within these communes, the intervention area was restricted to 12 
operational units, defined as the contiguous polygonal areas of 2000 residents with the highest 
predicted reproductive numbers. Models that integrated population density, surveillance data, 
population mobility scores, and ecological factors were used to predict risk of transmission and rank 
operational units. As potential sources of malaria transmission to the whole area, targeting the units 
with the highest current reproductive number would likely have spillover effects and reduce overall 
risk of infection31.  
Following a census, every household was visited and offered a treatment that comprised a single 
dose of SP + SLD-PQ (SP-PQ). The target dose for SP was 25/1.25 mg/kg, the approved therapeutic 
dose in Haiti for second-line treatment. The target dose for PQ was 0.25 mg/kg, lower than the 
recommended therapeutic dose. SP and SLD-PQ were chosen because they can be administered in a 
single dose and they have different therapeutic effects32. There is no indication of widespread P. 
falciparum resistance to PQ or SP in Haiti8.  
All individuals ≥6 months were offered directly observed, age-appropriate treatment of SP-PQ in a 
single dose. Women in their first trimester of pregnancy and participants with signs of severe illness, 
known allergies to SP or PQ, specific medical conditions, or using contra-indicated medications were 
excluded. Pregnant women in their second/third trimester and breastfeeding women were offered 
SP only. Return visits or mop-up distribution were arranged for those temporarily absent29.  
Simultaneously, a separate team led a tIRS campaign in the same area. Organophosphate insecticide 
pirimiphos methyl (Actellic 300CS) was applied once to each dwelling. It has a long residual activity 
(5-9 months) and no reported resistance in Haiti. Spraying was conducted after all individuals, 
animals and large pieces of furniture were removed from the household. Wall bioassays were 
performed to confirm quality of the insecticide application. 
Study Design 
This is an ecological, quasi-experimental study, using a pre- and post-test with nonrandomized 
control group to assess the effectiveness of tMDA+IRS on malaria parasite prevalence at the venue 
level33. Surveys were conducted November 6 - December 7, 2017, and November 12 - December 13, 
2018 in a panel of easy access groups (EAGs). Participants were recruited among the persons 
attending the EAG sites at the time of the survey. With a short lapse of time (1-5 weeks) between 
the campaign and the 2018 survey, the present study is designed to assess the intervention’s 
immediate effects. 
The intervention group includes all participants recruited in the EAGs located in intervention area. 



















Exposure is determined based on the EAG location, not on individual self-reported exposure to the 
intervention, nor on household location. More information about the EAG surveys is available 
elsewhere16. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines 
were followed (Supplementary file 1). 
Pilot Area, Easy Access Group Sampling 
The pilot area has a total estimated population of 156,138 within an area of 582 km2 (Figure 1). It is 
located in southwest Haiti, 10-hour drive from the capital. The pilot area is characterized by diverse 
environmental conditions: high mountains, rivers, lowlands, valleys, and dense forests. Three of the 
five included communes share a contiguous coastline. The population is mostly rural and hard-to-
reach, although a few towns have ˂20,000 inhabitants. Within the five communes, the area targeted 
for MDA+IRS covers 98 km2, with an estimated population of 46,372.  
Two types of EAGs were sampled in the pilot area: primary schools and health facilities (Figure 1). All 
health facilities (n=16) in the pilot area were included. For schools, after a census of all primary 
schools with at least 100 pupils, stratified random sampling was used to select 25 schools and ensure 
equal distribution across communes and by remoteness. The same EAGs was surveyed both years of 
the study. More information is available elsewhere16.  
Participants and Survey Procedures 
All new attending and accompanying persons in the health facilities were eligible to participate, 
except those who were attending a scheduled visit or required urgent care. In schools, all pupils 
were enrolled if their total number per school was <150; otherwise, a simple random sample of 150 
children was selected. A total of 5,000 participants were surveyed at each survey round. Participants 
were categorized into intervention vs. control group based on the location of the EAG where they 
were recruited. 
A socio-demographic questionnaire was administered to all participants. A capillary blood sample 
from a finger-prick was taken to perform a conventional histidine-rich protein 2-based (HRP2-based) 
RDT (SD Bioline Ag. Pf, South Korea). If invalid, it was repeated. Finger-prick blood was also spotted 
on Whatman 903 cards (GE Healthcare), dried overnight at ambient temperature and packed the 
next day with silica gel. The detailed procedure for recruiting and replacing participants is described 
elsewhere16. Refusal and drop-out rates were <1%. 
For the participants with RDT positive results, confirmation of P. falciparum infection was obtained 
by PCR34. Individuals with a positive RDT were provided the recommended first-line treatment. All 
participants testing positive by RDT and a random selection of 30% of those testing negative were 
traced to their household, where spatial coordinates were recorded using GPS devices (Garmin, 
Olathe, KS). 
Outcome and Statistical Analyses 
The unit of analyses is the EAG. The outcome for this study is the P. falciparum prevalence, 
estimated by the proportion of participants with a PCR-confirmed positive HRP2-based RDT. Because 
of the pseudo-panel structure of the study (EAGs being time-invariant, not the participants), effects 



















groups averaging method35,36. Intention-to-treat analysis was used; individuals within EAGs that 
were targeted for MDA+IRS were considered exposed (intervention group), while participants 
sampled from EAGs outside the targeted area were considered unexposed (control group). 
The average treatment effects were expressed as ratios of adjusted risk ratios (RaRR); i.e., the 
relative pre-post change in prevalence was compared between the intervention and control groups. 
This approach enables controlling for observed and unobserved time-invariant confounders37,38. 
RaRR (a relative term) is more appropriate than difference-in-differences (an absolute term) to 
assess changes when the two baseline measures differ39.  
Due to over-dispersion, a negative binomial regression model was fitted with the total count number 
of positive HRP2-based RDTs as the dependent variable, and the number of RDTs performed as the 
offset40. Potential time-varying confounding variables were tested in the model: socio-demographic 
characteristics, use of LLINs, travel history, and total rainfall during the previous 2 months. The final 
model included LLIN use (averaged at the venue level) and rainfall (at 5 km resolution), with the best 
fitting model selected according to the Akaike information criterion values. Cluster-robust variance 
estimators were consistently used41.  
Sensitivity analyses were conducted by splitting the intervention group in two sub-groups, with the 
median MDA coverage among the EAGs located in the intervention area (60%) used as the cut-off. 
The exposure variable was therefore redefined into three categories: control group, low (<60%), and 
high (≥60%) MDA coverage.  
All analyses were performed using Stata 14.0 (StataCorp LLC, College Station, Texas). Maps were 
produced using QGIS v3.8.1 Zanzibar (open source software with general public license). Rainfall 
data was extracted from the climate hazards precipitation with station database. 
Ethics  
Consent procedures are detailed elsewhere16. In health facilities, informed written consent was 
sought from adult participants and from parents/guardians of children (<18 years). In schools, an 
opt-out method was used to obtain consent from the children’s parents. Written assent was sought 
for children above 6 years of age. Participants could choose to give thumbprint consent/assent if 
they could not sign.  
The study was approved by the research committee in Haiti (1516-30), the London School of Hygiene 
& Tropical Medicine Ethics Committee (103939), and Tulane University Institutional Review Board 
(795709). Participation in the study was not remunerated. Activity did not constitute engagement in 
human subjects research as determined by the US Centers for Disease Control and Prevention (CDC) 























A total of 10,006 participants were recruited in 41 EAGs (Table 1), 19 of which were located in the 
intervention area (Figure 1). In 2017, 48% of the 5,026 participants were recruited in the area that 
was later targeted for intervention. In 2018, 42% (2,094 out of 4,980) of the participants were 
recruited in the intervention area, of which 59% (n=1,238) reported that their household was visited 
for the campaign. Among these, 86% (n=1,089) reported having taken MDA in the previous weeks. 
The primary reasons for not having taken MDA despite the household visit were: being absent 
(n=74), being excluded (n=37), and refusal (n=12). Among the participants recruited in 2018 in the 
control area, less than 2% (n=47) reported having been exposed to MDA. Regarding IRS, 33% (n=683) 
of participants recruited in the intervention area reported that their household had been sprayed in 
the previous weeks vs. 6% (n=168) in the control area. In the intervention area, PCR-confirmed RDT 
positivity was significantly associated in bivariate analysis with self-reported exposure to MDA (OR = 
0.15, 95% CI [0.070–0.356]), but not to IRS (OR = 0.73, 95% CI [0.374–1.430]). About 86% (2017) and 
92% (2018) of RDT positive samples were confirmed by PCR. 
Effects on P. falciparum prevalence 
At baseline, prevalence was higher in the EAGs located in the intervention area (ranging 0–30%) 
compared to the control area (ranging 0–12%) (Table 2). This was expected since the intervention 
was implemented in the highest transmission areas. Prevalence diminished between 2017 and 2018 
in both areas (Figure 2), but the reduction was significantly larger in the intervention area. Intent-to-
treat analysis predicts a 68% further reduction in malaria prevalence (RaRR = 0.32, 95% CI [0.103–
0.998]), after adjusting for LLIN use and rainfall (Table 3).  
Visual observation of the data and the unadjusted coefficient of determination suggested that 
prevalence was correlated to self-reported exposure to MDA (Figure 3), but not to self-reported 
exposure to IRS (Supplementary File 2). Sensitivity analyses were therefore conducted by 
categorizing EAGs in the intervention area as low (<60%) versus high (≥60%) rates of self-reported 
exposure to MDA (Figure 4). A dose-response gradient was observed. Indeed, when compared to the 
control area, the EAG with low MDA coverage present a non-significant 15% further reduction in 
malaria prevalence (RaRR = 0.85, 95% CI [0.270 – 2.719]), in contrast to the 79% reduction in the 
EAG with high MDA coverage (RaRR = 0.21, 95% CI [0.054 - 0.812]).  
Sensitivity analysis 
A per-protocol analysis was also performed for “adherent” participants (n=9,017) – those who either 
reported having taken MDA and were recruited in the intervention area, or reported having not 
taken MDA and were recruited in the control area. Per-protocol analysis suggests that the 























The findings indicate that the MDA+IRS campaign was associated with an immediate reduction in 
malaria parasite prevalence by 68%, which was statistically significant but with a wide uncertainty 
range. Sensitivity analyses suggest that the effectiveness would have increased if more of the 
participants recruited in the intervention area would have been exposed to it. In the subgroup of 
EAGs with tMDA coverage ≥60%, its effectiveness in reducing malaria prevalence reached 79%, close 
to the 86% effectiveness obtained in the per-protocol analysis.   
Our estimate is smaller than the 97% reduction within 1 month post-MDA that was found in a recent 
meta-analysis of studies conducted in settings with moderate endemicity21 – but those studies took 
place decades ago in Kenya and India, and did not use the same drug regimen. Results from the 
present study are also difficult to compare with the evaluation of repeated MDA campaigns that 
took place in Haiti in the 1960s using chloroquine and pyrimethamine42. The true effect is likely 
underestimated in the present evaluation, most importantly because of the moderate MDA (54%) 
and IRS (33%) coverage in the intervention area. Misclassification errors between the targeted and 
control areas are also possible since catchment populations of EAGs do not perfectly overlap with 
these respective areas, although this error concerned only 2.7% (46/1682) of the geolocated 
households (Supplementary Files 3 & 4). These factors would bias the results towards a null effect.  
This study cannot disentangle the effects of the two components of the intervention, since they 
overlapped in time and space. However, it is unlikely that the estimated effects can be attributed to 
the tIRS component. Indeed, IRS generally requires intensive campaigns to reduce malaria 
transmission, with high coverage (above 80%) and multiple rounds of administration43,44. In addition, 
they do not affect the parasite reservoir in infected individuals, but rather reduce transmission and 
protect the population from later resurgence45. Unsurprisingly, our analyses have not found 
evidence of an association between self-reported exposure to IRS and malaria prevalence in the 
targeted sites.  
Under such conditions, the estimated prevalence reduction is very encouraging, especially after only 
one round. Targeting the areas with the greatest risk of malaria transmission immediately reduced 
the gap between the low-risk and high-risk zones. When comparing baseline to endline, the 
proportion of EAGs with prevalence <1% increased from 21% to 68% in the targeted area, and from 
68% to 91% in the control area. The impact could be optimized by adding tMDA+IRS rounds and by 
reaching more people in the intervention area21,22. As prevalence decreases (<3%), the strategy 
might be refined to identify the remaining asymptomatic reservoir populations and redirect 
aggressive MDA+IRS campaigns toward them to further progress to elimination23. However, the 
timing of switching strategies is problematic. Indeed, the benefits of MDA are transient, but 
identifying the asymptomatic reservoir takes time and remains difficult until overall transmission is 
already low25,46. 
Targeted MDA+IRS is recommended when foci are clustered in small areas, especially with high 
population mobility23. Studies conducted in Grande-Anse have suggested that malaria infections are 
locally acquired; the Department was portrayed as a source rather than a sink of cases11,16. By 
targeting the areas with the highest predicted malaria risk in Grande-Anse, the intervention was 



















MDA (or received IRS) or not. Our results are congruent with (but cannot establish) the presence of a 
“community effect”, – since malaria prevalence also decreased in the control area and among those 
non-exposed in the intervention area, even after adjusting for rainfall.  
This is an ecological study and, as such, does not purport to assess causal inference or draw 
conclusions at the individual level. Rather, it examines the intervention’s effects on malaria 
prevalence in the overall catchment population of EAG venues. The aggregation of individual data at 
the EAG level was required to obtain a panel structure and strengthen the robustness of the 
evaluation design. Unfortunately, this rendered the study ecological and reduced statistical power of 
the analysis. Furthermore, the surveys in the easy access groups were planned before -and 
independently of- the intervention. Both surveys were carried out during the same period of the 
year to increase their comparability, even if it meant examining only the immediate effects of the 
intervention. 
Only a portion of the EAG catchment populations (i.e., those who live in the areas with the highest 
predicted risk) were targeted for MDA+IRS. It was therefore anticipated to assess an intervention 
whose coverage would be moderate at best. More than a limitation, this constitutes one of this 
study’s unique characteristics. Instead of randomized clinical trial conditions, this is one of the first 
evaluations of a highly targeted MDA+IRS campaign47. This echoes our intention to inform 
programmatic efforts about potential strategies to accelerate progress towards malaria elimination, 
rather than to establish the protective effects of MDA campaigns in Haiti using SP-PQ - likely to be 
exceptionally high due to the absence of resistance. In the same vein, this study does not claim to 
assess MDA+IRS coverage or P. falciparum prevalence in the general population. 
Repeated surveys in easy access groups are helpful in designing quasi-experimental studies, even if 
the intervention is not implemented by the research team (natural experiment design) 48. The 
difference-in-differences approach that was used allowed to control for time-invariant observable 
and non-observable confounding factors. The influence of potential time-varying confounding 
factors, such as rainfall and LLIN usage, was tested and adjusted for. Analyses, including bilateral 
tests and cluster-robust variance estimators, were intentionally conservative. However, the disparity 
in malaria prevalence at baseline between the control and intervention groups may have affected 
the observed effect size. RaRRs were preferred over difference-in-differences to minimize this risk. It 
is still possible that trends in relative changes were dissimilar during pre-intervention period 
between the two groups. Unfortunately, this hypothesis could not be tested due to the lack of pre-
baseline survey data. Although an imperfect proxy for prevalence, passive surveillance data does not 
suggest different pre-intervention trends between the groups of health facilities. 
Other interventions were implemented during the time interval, which might have affected our 
estimates. However, the context was closely monitored and exposure to other types of interventions 
(such as LLINs distribution) was controlled for in the models. Finally, information bias is possible, 
especially in school-aged children. Several measures were taken to minimize this risk (described 






















This study measured the immediate effects associated with a tMDA+IRS campaign against malaria in 
Grande-Anse Department, Haiti. The campaign was restricted to the areas with the highest predicted 
malaria risk. While coverage was only moderate in the study population, the campaign was 
significantly associated with a 68% reduction in malaria prevalence immediately after one round. 
Further evaluation of the campaign is being conducted and will be published in forthcoming papers. 
Targeted MDA+IRS can be used in pre-elimination settings to rapidly reduce malaria transmission, 
which is an encouraging step to accelerate progress towards elimination depending on local 
vectorial capacity and importation risk. Repeated surveys in easy access groups provide an 






















CI Confidence interval 
EAG Easy access groups 
IRS Indoor residual spraying 
GPS Global positioning system 
HRP2 Histidine-rich protein-2 
MDA Mass drug administration 
SLD-PQ Single Low-Dose Primaquine 
RaRR Ratio of adjusted risk ratios 
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Map of the five communes of the pilot area in Grande-Anse Department, Haiti. The 41 EAGs are 
represented as blue diamonds (for schools) or as red crosses (for health facilities). The intervention 
area targeted for MDA and IRS is displayed in orange.  
EAG easy access groups; MDA mass drug administration; IRS indoor residual spraying  
 
Figure 2 
Observed and predicted trends in P. falciparum prevalence per EAG between 2017 and 2018. 
Parasite prevalence was measured by RDT, with PCR confirmation of positive cases. Predicted trend 
was derived from a negative binomial model with the total number of positive cases as the 
dependent variable, the total number of tests performed as the offset, and the area type 
(intervention vs. control) as exposure. The model was adjusted for potential time-varying 
confounding variables.  
EAG easy access group; RDT rapid diagnostic test; PCR polymerase chain reaction.  
 
Figure 3 
Relative difference in P. falciparum prevalence per EAG between 2017 and 2018, characterized by 
MDA coverage per EAG in 2018. MDA coverage per EAG is defined as the % of participants that self-
reported having received MDA treatment in the previous weeks. P. falciparum prevalence is 
expressed as the % of positive RDT out of the total number of tests performed per EAG. The 
association was assessed by fitting a quadratic function (y=+x+x2). The coefficient of 
determination (i.e.: % of variance explained by MDA coverage) equals 51.17%.  
MDA Mass drug administration; EAG easy access group; RDT rapid diagnostic test. 
 
Figure 4 
Risk ratios of malaria, 2018 vs. 2017, with their 95% CI and by levels of MDA coverage. MDA 
coverage per EAG is defined based on the proportion of participants that self-reported having taken 
MDA in the previous weeks. The exposure variable was redefined based on three categories: control 
area, intervention area with MDA coverage <60% and intervention area with MDA coverage ≥60%.  




















Table 1  Participants characteristics, by intervention area and year 
 
Intervention area Control area 
 
2017 2018 p-value 2017 2018 p-value 




Female  0.56 0.59 0.092 0.51 0.55 0.003 
Slept under a bednet the night before 0.57 0.47 <0.001 0.42 0.27 <0.001 
Age group of participant 




5-14 years 0.46 0.42 0.49 0.51 
15-29 years 0.25 0.24 0.23 0.22 
30-45 years 0.09 0.1 0.09 0.07 
>45 years 0.09 0.09 0.1 0.07 
Travelled in the past 3 months 0.03 0.04 0.004 0.04 0.03 0.119 
History of fever in the past 2 weeks 0.16 0.15 0.692 0.11 0.13 0.022 
Household size is >5 0.52 0.53 0.207 0.55 0.58 0.049 
Household owns livestock 0.45 0.53 <0.001 0.61 0.63 0.165 
Household owns bed net(s) 0.68 0.59 <0.001 0.57 0.39 <0.001 
Occupation of the head of the household 
Farmer 0.54 0.41 
<0.001 
0.71 0.62 
<0.001 Shop keeper 0.25 0.37 0.14 0.21 
Other 0.21 0.22 0.15 0.17 
Urban area 0.59 0.6 0.422 0.28 0.28 0.695 
Commune 




Chambellan 0.36 0.34 0 0 
Dame-Marie 0.24 0.25 0.36 0.37 
Anse-d'Hainault 0.07 0.06 0.48 0.42 
Les Irois 0.06 0.06 0.16 0.21 
Took MDA 0 0.54 <0.001 0 0.02 <0.001 
Household was sprayed (IRS) 0 0.34 <0.001 0 0.06 <0.001 


























2017 2018 Difference in means¶ 2017 2018 Difference in means¶ 
Total number of sites 22 22 
 
19 19 
 Number of participants per site 118 130 -12.5 128  110  18.6 
Age of participants (in years) 16 16 -0.8 17  16 -0.7 
% of female participants 0.494 0.539 -0.044 0.548  0.571 -0.022 
% of participants who slept under a bed net the night before 0.416 0.266 -0.150** 0.546 0.479 -0.068 
% of participants who traveled recently 0.027 0.026 -0.001 0.021 0.031 0.010 
% of large households (>5 members) 0.552 0.563 0.020 0.532 0.567 0.035 
% of households that owns cattle 0.624 0.642 0.017 0.458 0.548 0.090 
% of farming households  0.741 0.637 -0.104 0.592 0.492 -0.100 
Total rain precipitation over the previous 2 months (in mm) 330 230 -100*** 330 234 -95*** 
% of participants with positive RDT (confirmed by PCR) 0.015 0.005 -0.010 0.091 0.017 -0.074** 
¶ Tests on the equality of means tha  are statistically significant are marked (* p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001) 

























Pre-intervention Post-intervention Adjusted risk ratio 95% CI p-value 
Control area 1.32% 0.52% 0.394 [0.073 ; 2.109] 0.276 
Intervention area 14.28% 1.80% 0.126 [0.022 ; 0.724] 0.020 
      
Ratio of adjusted risk ratios 0.321 [0.104 : 0.998] 0.049 
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